FI117911B - Vasta-ainetuotannon toteaminen - Google Patents

Vasta-ainetuotannon toteaminen Download PDF

Info

Publication number: FI117911B
Authority: FI; Finland
Prior art keywords: antibodies; antibody; solid phase; sample; lymphocytes
Prior art date: 1995-02-21

Application number

FI973418A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI973418A0 (fi

FI973418L (fi

Inventor

Lars Reinhardt Haaheim

Original Assignee

Plasmacute As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-21

Filing date

1997-08-20

Publication date

2007-04-13

1997-08-20 Application filed by Plasmacute As filed Critical Plasmacute As

1997-08-20 Publication of FI973418A0 publication Critical patent/FI973418A0/fi

1997-08-20 Publication of FI973418L publication Critical patent/FI973418L/fi

2007-04-13 Application granted granted Critical

2007-04-13 Publication of FI117911B publication Critical patent/FI117911B/fi

Links

238000001514 detection method Methods 0.000 title claims abstract description 24
238000004519 manufacturing process Methods 0.000 title claims description 4
238000000034 method Methods 0.000 claims abstract description 86
239000000427 antigen Substances 0.000 claims abstract description 74
102000036639 antigens Human genes 0.000 claims abstract description 74
108091007433 antigens Proteins 0.000 claims abstract description 74
210000004698 lymphocyte Anatomy 0.000 claims abstract description 61
210000004369 blood Anatomy 0.000 claims abstract description 38
239000008280 blood Substances 0.000 claims abstract description 38
230000027455 binding Effects 0.000 claims abstract description 37
239000007790 solid phase Substances 0.000 claims abstract description 36
208000015181 infectious disease Diseases 0.000 claims abstract description 29
230000016784 immunoglobulin production Effects 0.000 claims abstract description 20
230000004044 response Effects 0.000 claims abstract description 18
229940123573 Protein synthesis inhibitor Drugs 0.000 claims abstract description 16
239000000007 protein synthesis inhibitor Substances 0.000 claims abstract description 16
230000028327 secretion Effects 0.000 claims abstract description 14
238000002965 ELISA Methods 0.000 claims description 34
241000700605 Viruses Species 0.000 claims description 15
239000000758 substrate Substances 0.000 claims description 10
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical group C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 claims description 9
238000003018 immunoassay Methods 0.000 claims description 9
230000008569 process Effects 0.000 claims description 9
239000003112 inhibitor Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 6
230000002458 infectious effect Effects 0.000 claims description 2
239000013642 negative control Substances 0.000 claims description 2
238000000746 purification Methods 0.000 claims description 2
230000003100 immobilizing effect Effects 0.000 claims 2
229940121819 ATPase inhibitor Drugs 0.000 claims 1
239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
210000005036 nerve Anatomy 0.000 claims 1
238000003556 assay Methods 0.000 description 61
210000004027 cell Anatomy 0.000 description 50
238000012360 testing method Methods 0.000 description 23
210000002966 serum Anatomy 0.000 description 18
238000011534 incubation Methods 0.000 description 15
239000002609 medium Substances 0.000 description 15
238000003786 synthesis reaction Methods 0.000 description 12
238000002835 absorbance Methods 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
239000000243 solution Substances 0.000 description 10
241000701074 Human alphaherpesvirus 2 Species 0.000 description 9
102000003992 Peroxidases Human genes 0.000 description 8
108040007629 peroxidase activity proteins Proteins 0.000 description 8
238000002255 vaccination Methods 0.000 description 8
239000000562 conjugate Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
230000002269 spontaneous effect Effects 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
229960002897 heparin Drugs 0.000 description 6
229920000669 heparin Polymers 0.000 description 6
230000028993 immune response Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
238000005406 washing Methods 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
210000000628 antibody-producing cell Anatomy 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
206010022000 influenza Diseases 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
238000000926 separation method Methods 0.000 description 5
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
235000012431 wafers Nutrition 0.000 description 5
238000012286 ELISA Assay Methods 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
229960003971 influenza vaccine Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002955 isolation Methods 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 3
241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
230000003622 anti-hsv Effects 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
239000011616 biotin Substances 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
239000012678 infectious agent Substances 0.000 description 3
238000001243 protein synthesis Methods 0.000 description 3
230000000405 serological effect Effects 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000012089 stop solution Substances 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
229960000814 tetanus toxoid Drugs 0.000 description 3
230000014616 translation Effects 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
HRDVWDQQYABHGH-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline hydrochloride Chemical compound Cl.CN(C)c1ccc(cc1)-c1ccc(cc1)N(C)C HRDVWDQQYABHGH-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000010836 blood and blood product Substances 0.000 description 2
229940125691 blood product Drugs 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000003759 clinical diagnosis Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
238000003312 immunocapture Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000015654 memory Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
-1 plates Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
101150066375 35 gene Proteins 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
240000007124 Brassica oleracea Species 0.000 description 1
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
101100316805 Caenorhabditis elegans spe-5 gene Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000000981 bystander Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000007981 phosphate-citrate buffer Substances 0.000 description 1
238000009372 pisciculture Methods 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012205 qualitative assay Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000012206 semi-quantitative assay Methods 0.000 description 1
238000009589 serological test Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
241000894007 species Species 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
229940031418 trivalent vaccine Drugs 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Virology (AREA)
Food Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Pathology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

FI973418A 1995-02-21 1997-08-20 Vasta-ainetuotannon toteaminen FI117911B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB9503406		1995-02-21
GBGB9503406.2A GB9503406D0 (en)	1995-02-21	1995-02-21	Detection of antibody production
PCT/GB1996/000392 WO1996026443A1 (en)	1995-02-21	1996-02-21	Detection of antibody production
GB9600392		1996-02-21

Publications (3)

Publication Number	Publication Date
FI973418A0 FI973418A0 (fi)	1997-08-20
FI973418L FI973418L (fi)	1997-08-20
FI117911B true FI117911B (fi)	2007-04-13

Family

ID=10769981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI973418A FI117911B (fi)	1995-02-21	1997-08-20	Vasta-ainetuotannon toteaminen

Country Status (21)

Country	Link
US (1)	US6080552A (pt)
EP (1)	EP0811165B1 (pt)
JP (1)	JP3472929B2 (pt)
CN (1)	CN1098460C (pt)
AT (1)	ATE188551T1 (pt)
AU (1)	AU709591B2 (pt)
CA (1)	CA2213083C (pt)
CZ (1)	CZ289582B6 (pt)
DE (1)	DE69606024T2 (pt)
DK (1)	DK0811165T3 (pt)
ES (1)	ES2140821T3 (pt)
FI (1)	FI117911B (pt)
GB (1)	GB9503406D0 (pt)
GR (1)	GR3032740T3 (pt)
HU (1)	HU225687B1 (pt)
NO (1)	NO317151B1 (pt)
NZ (1)	NZ301770A (pt)
PL (1)	PL182061B1 (pt)
PT (1)	PT811165E (pt)
RU (1)	RU2197733C2 (pt)
WO (1)	WO1996026443A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0955544A1 (de) *	1998-05-06	1999-11-10	Hölzel Diagnostika Handels GmbH	Verfahren zum Erfassen von Primärsignalen bei der Zellkommunikation von Zellen des Immunsystems
GB9913819D0 (en) *	1999-06-14	1999-08-11	Plasmacute As	Assay
GB0325483D0 (en) *	2003-10-31	2003-12-03	Plasmacute As	Assay
US20050240353A1 (en) *	2004-04-21	2005-10-27	Hoffmann Technologies Corporation	Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research
JP4412732B2 (ja) *	2005-04-19	2010-02-10	独立行政法人国立高等専門学校機構	リンパ球を利用した抗体検査方法および病原体特定方法
DE102007052518A1 (de) *	2007-10-29	2009-04-30	Autoimmun Diagnostika Gmbh	Verfahren zur in vitro-Diagnose und/oder in vitro- Therapieverfolgung von Infektionen
RU2422831C1 (ru) *	2009-10-19	2011-06-27	Учреждение Российской Академии Медицинских Наук Нии Общей Патологии И Патофизиологии Рамн	Экспресс-способ определения нарушения иммунного статуса организма человека
AU2015257417A1 (en)	2014-05-05	2016-11-03	Cembre S.P.A.	Machine for the application and / or removal of connecting fasteners for rails
RU2756764C1 (ru) *	2021-06-09	2021-10-05	Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России)	Способ определения функциональной активности системы комплемента человека для прогноза тяжести течения системной воспалительной реакции

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5019497A (en) *	1984-11-09	1991-05-28	Lennart Olsson	Human squamous lung carcinoma cell specific antigens and antibodies
US4707443A (en) *	1985-04-19	1987-11-17	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same
CA2011099A1 (en) *	1989-04-19	1990-10-19	Stephen C. Wardlaw	Determination of lymphocyte reactivity to specific antigens in blood
US5188942A (en) *	1990-10-09	1993-02-23	Consultants For Applied Biosciences, Inc.	Method for determining bluetongue virus antibodies in serum

1995
- 1995-02-21 GB GBGB9503406.2A patent/GB9503406D0/en active Pending
1996
- 1996-02-21 ES ES96903122T patent/ES2140821T3/es not_active Expired - Lifetime
- 1996-02-21 DE DE69606024T patent/DE69606024T2/de not_active Expired - Lifetime
- 1996-02-21 HU HU9801448A patent/HU225687B1/hu not_active IP Right Cessation
- 1996-02-21 AU AU47268/96A patent/AU709591B2/en not_active Ceased
- 1996-02-21 EP EP96903122A patent/EP0811165B1/en not_active Expired - Lifetime
- 1996-02-21 CA CA002213083A patent/CA2213083C/en not_active Expired - Fee Related
- 1996-02-21 DK DK96903122T patent/DK0811165T3/da active
- 1996-02-21 CZ CZ19972634A patent/CZ289582B6/cs not_active IP Right Cessation
- 1996-02-21 NZ NZ301770A patent/NZ301770A/en not_active IP Right Cessation
- 1996-02-21 JP JP52549296A patent/JP3472929B2/ja not_active Expired - Fee Related
- 1996-02-21 PT PT96903122T patent/PT811165E/pt unknown
- 1996-02-21 CN CN96192047A patent/CN1098460C/zh not_active Expired - Fee Related
- 1996-02-21 WO PCT/GB1996/000392 patent/WO1996026443A1/en not_active Ceased
- 1996-02-21 US US08/913,137 patent/US6080552A/en not_active Expired - Fee Related
- 1996-02-21 AT AT96903122T patent/ATE188551T1/de not_active IP Right Cessation
- 1996-02-21 RU RU97115554/13A patent/RU2197733C2/ru not_active IP Right Cessation
1997
- 1997-08-14 PL PL96322209A patent/PL182061B1/pl not_active IP Right Cessation
- 1997-08-20 NO NO19973823A patent/NO317151B1/no not_active IP Right Cessation
- 1997-08-20 FI FI973418A patent/FI117911B/fi not_active IP Right Cessation
2000
- 2000-02-23 GR GR20000400440T patent/GR3032740T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69606024T2 (de)	2000-09-14
US6080552A (en)	2000-06-27
NZ301770A (en)	1999-04-29
ATE188551T1 (de)	2000-01-15
JP3472929B2 (ja)	2003-12-02
HUP9801448A3 (en)	2000-09-28
DE69606024D1 (de)	2000-02-10
NO317151B1 (no)	2004-08-30
CN1098460C (zh)	2003-01-08
GB9503406D0 (en)	1995-04-12
PL182061B1 (pl)	2001-10-31
RU2197733C2 (ru)	2003-01-27
CA2213083A1 (en)	1996-08-29
EP0811165A1 (en)	1997-12-10
NO973823D0 (no)	1997-08-20
AU709591B2 (en)	1999-09-02
DK0811165T3 (da)	2000-05-08
EP0811165B1 (en)	2000-01-05
CZ289582B6 (cs)	2002-02-13
CN1176000A (zh)	1998-03-11
PL322209A1 (en)	1998-01-19
NO973823L (no)	1997-10-20
CZ263497A3 (cs)	1998-02-18
GR3032740T3 (en)	2000-06-30
WO1996026443A1 (en)	1996-08-29
PT811165E (pt)	2000-04-28
AU4726896A (en)	1996-09-11
FI973418A0 (fi)	1997-08-20
HUP9801448A2 (hu)	1998-10-28
FI973418L (fi)	1997-08-20
ES2140821T3 (es)	2000-03-01
HU225687B1 (en)	2007-06-28
CA2213083C (en)	2007-12-04
JPH11500226A (ja)	1999-01-06

Publication	Publication Date	Title
EP0216191B1 (en)	1991-06-19	Immunoassay for htlv-iii antigens
CA1340109C (en)	1998-11-03	Immunoassay for hiv-1 antigens using f(ab')2 fragments as probe
KR101753580B1 (ko)	2017-07-06	브루셀라 캐니스 항원의 제조 방법
FI117911B (fi)	2007-04-13	Vasta-ainetuotannon toteaminen
US20080206790A1 (en)	2008-08-28	Assay for determining the presence or amount of newly synthesized antibodies
EP0366673B1 (en)	1992-09-16	Immunoassay method
US20070292839A1 (en)	2007-12-20	Assay
Descoteaux et al.	1981	Comparison of hemagglutination inhibition, serum neutralization and ELISA-PVM tests for the detection of antibodies to pneumonia virus of mice in rat sera
Boteler et al.	1984	Multicenter evaluation of a 1-h enzyme-linked immunosorbent assay for rubella serology
CN110596382A (zh)	2019-12-20	一种结核病诊断试剂盒及其制备方法

Legal Events

Date	Code	Title	Description
2004-11-02	PC	Transfer of assignment of patent	Owner name: PLASMACUTE AS
2007-04-13	FG	Patent granted	Ref document number: 117911 Country of ref document: FI
2011-09-28	MM	Patent lapsed

Date

Code

Title

Description

2004-11-02

Transfer of assignment of patent

Owner name: PLASMACUTE AS